Canadian regulators give InSightec a nod of approval for the ExAblate system to treat benign uterine tumors and painful metastatic bone tumors.
Canadian healthcare regulators approved InSightec's ExAblate ultrasound system, clearing the device for use against 2 different diseases. Health Canada granted ExAblate indication to break up benign uterine tumors and to alleviate painful symptoms of metastatic bone tumors.
The Tirat Carmel, Israel-based company specializes in ultrasound ablation technology. InSightec's ExAblate uses a highly focused beam, guided by an MRI, to break up tissue. The tumor-busting procedure uses non-iodizing radiation and alleviates symptoms without surgical removal.